These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 28797284)

  • 1. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
    Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
    J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
    Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
    Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
    Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
    Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
    Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
    Rüstem DG; Atay S; Aydin HH; Ak H
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2204-2215. PubMed ID: 33397269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
    PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
    Liu Q; Song C; Li J; Liu M; Fu L; Jiang J; Zeng Z; Zhu H
    Med Oncol; 2022 Jun; 39(9):124. PubMed ID: 35716217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
    Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
    World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
    J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
    Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
    Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
    Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
    Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P
    Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
    Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
    Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
    Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
    Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.